Positive clinical results of ACP-001 presented at EHA2022
/PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its...
Source: prnewswire.com
Stay updated with breaking news from Hareth Nahi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its...
STOCKHOLM, June 10, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate
Positive clinical results of ACP-001 presented at EHA2022
/PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its...